GlaxoSmithKline's long-lasting triple inhalation agent "Full Re-Le" gets listing approval from China's State Drug Administration
-
Last Update: 2020-06-07
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
Today, GlaxoSmithKline (GSK) announced that Trelegy ® Ellipta ®, a long-acting triple inhalation agent for slow-obstructed lung stabilization, has been approved by theRegulatory Authority of china's nationalmedicine
s (http:// regulatory agencyWhole Rele contains three drug components: inhaled glucocorticoid (ICS), long-acting anticholinergicdrug(http://(LAMA) and long-acting beta2 receptor agonist (LABA), which can be given once a day through GSK's unique Ellipta ® dry powder inhalation deviceFull Rele Phase III Clinical Study - THE FULFIL Study shows that Full Rele significantly improves patients' quality of life and lung function compared to a clinically commonIC/LABA formulation, and significantly reduces acute exacerbation in patients with COPDIn another Phase III clinical study of 10,355 patients with CPR, IMPACT, Total Rele significantly outperformed dicombination therapy in key clinical indicators such as reducing acute exacerbation in patients with coptal-impedance, improving lung function and quality of life, including inhaled glucocorticoids/long-acting beta-2 receptor agonists (ICS/LABA), and long-acting anti-biliary drugs/long-actant beta2 receptor agonists (LAMA/LABA)Total Rele is currently the only triple drug (vsLAMA/LABA)
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
